Cell and Gene Therapy Editing and Proofreading Services

A patient is being asked to accept a treatment given once, which cannot be stopped, reversed or reduced if it turns out to be too much. Everything they know about medicine — that you try it, and if it disagrees with you the doctor changes it — does not apply. Explaining this in a way that a frightened person can genuinely take in is one of the hardest writing tasks in medicine, and most documents in this field were not written for them.

We edit what cell and gene therapy developers and centres produce — patient information and consent material for one-time treatments, long-term follow-up explanations and commitments, apheresis, conditioning and infusion process descriptions, risk communication for cytokine release syndrome, neurotoxicity and insertional events, eligibility and screening explanations, caregiver and family guidance, treatment centre and referral pathway information, manufacturing and turnaround time communications, expanded access and clinical trial material, and payer and reimbursement documentation for one-off therapies. Our editors work on the explanation of a decision that cannot be undone.

Communicating irreversibility is the central writing problem in this field, and the failure is applying the register of ordinary medicine to something that does not work like it. A leaflet listing side effects in the usual way implies the usual remedy — tell your doctor and something will be adjusted. We work through these so the one-time nature is stated early and directly, with what it means practically: this is given once, it cannot be removed, and if the effects are severe they are managed rather than stopped; so the timeline is laid out as a sequence the patient will actually live through — screening, cells collected, weeks of waiting while they are made, conditioning that will make them very unwell, infusion, the fortnight when the serious risks occur, and then years; so the long-term follow-up commitment is stated in years with what it involves, because signing up to fifteen years of monitoring is part of the decision and is routinely mentioned last; so the manufacturing failure possibility is included, given that being told after apheresis that the product could not be made is a devastating event nobody was prepared for; so uncertainty about long-term effects is admitted plainly rather than described as being studied; and so the alternative, including no treatment, is described with the same care. Documents written this way support a decision rather than a signature.

Everything you send is treated in confidence, including protocols, patient material and unpublished data. We are editors rather than clinicians, scientists or regulatory advisers, and we offer no view on treatments, risks or eligibility. What we can do is make an irreversible decision understandable to the person making it.